E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052066 |
E.1.2 | Term | Metabolic syndrome |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the effect of eplerenone on endothelial function of retinal arterioles in patients with metabolic function |
|
E.2.2 | Secondary objectives of the trial |
To investigate the effect of eplerenone in metabolic syndrome on - flow mediated dilation of the brachial artery - distensibility of the carotid artery - parameters of lipid and glucose metabolism - steroid hormones (aldosterone, cortisone, cortisol) in serum and urine |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male patients aged > 18 years • with mild uncomplicated primary arterial hypertension with a mean sitting SPB ≥ 130 mmHg or DBP ≥ 85 mmHg or treated hypertension and • at least 2 of the following traits of the metabolic syndrome (ATP III criteria): • abdominal obesity (abdominal girth ≥ 88 cm in females and ≥ 102 cm in males), • triglyceride level ≥ 150 mg/dL or treatment for elevated triglyzerides, • HDL < 40 mg/dL for men and < 50 mg/dL for women or treatment for low HDL • fasting blood glucose ≥ 100 mg/dL and ≤ 126 mg/dl.
• Written informed consent • Agreement to attend all study visits as planned in the protocol
|
|
E.4 | Principal exclusion criteria |
•• Patients with or without antihypertensive therapy and average blood pressure > 160/100 mmHg • Patients with secondary hypertension • Patients with one antihypertensive agent maximally dosed or two (or less) agents with half (or less) of maximum approved dose • Patients with diabetes mellitus type 1 or type 2 • Smokers and ex-smokers < 1 year • Female patients (to prevent effects of changes in endothelial function attributable to the menstrual cycle) • Patients with sick sinus syndrome • Patients with higher degree of sinoatrial or atrioventricular block (II-III) • Patients with bradycardia (< 50 beats/min) • Patients with malignant arrhythmias • Patients with known cardiovascular, disease • Patients with known cerebrovacular disease • Patients with peripheral occlusive artery disease • Patients with history of epilepsy • Patients with severe hepatic disease (serum GOT, GPT, -GT, AP, bilirubin > 300 of uppper normal range) • Patients with renal disease defined by eGFR < 60 ml/min/1,73m2 • Patients with history of malignant disease within the last 2 years • Patients with history of depression • Patients with drug or alcohol abuse • Use of any investigational drug within 28 days before study entry • Known allergy or a known intolerance to the study drug • Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol, especially likelihood of the need for additional antihypertensive medication • Serious disorders which may limit the ability to evaluate the efficacy or safety of the test drug(s), including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological or oncological, neurological and psychiatric diseases • Subject is the investigator or any subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol • Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study • Subject unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for follow-up visits and unlikelihood of completing the study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change of basal nitric oxide activity (as assessed by change of retinal capillary flow in response to nitric oxide inhibition) after ten weeks of treatment with eplerenone. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |